KalVista Pharmaceuticals (KALV) Shares Outstanding (Weighted Average) (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Shares Outstanding (Weighted Average) of $53.5 million in Q3 2025, up 7.74% quarter-over-quarter from $49.7 million in Q2 2025, and up 15.71% year-over-year from $46.2 million in Q3 2024.
KalVista Pharmaceuticals' Shares Outstanding (Weighted Average) history runs 12 years deep, the most recent figure standing at $53.5 million for Q3 2025.
- In Q3 2025, Shares Outstanding (Weighted Average) rose 15.71% year-over-year to $53.5 million; the TTM figure through Jul 2025 stood at $53.5 million (up 15.71% YoY), while the FY2025 annual figure was $49.7 million, up 34.98% from the prior year.
- Shares Outstanding (Weighted Average) came in at $53.5 million for Q3 2025 at KalVista Pharmaceuticals, up from $49.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $53.5 million in Q3 2025 to a low of $18.0 million in Q1 2021.
- A 5-year average of $32.9 million and a median of $28.3 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
- Across the five-year window, Shares Outstanding (Weighted Average) increased 0.52% in 2022 and jumped 40.65% in 2023, its largest moves.
- KalVista Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $24.4 million in 2021, then increased by 0.56% to $24.6 million in 2022, then surged by 40.65% to $34.6 million in 2023, then surged by 43.01% to $49.4 million in 2024, then grew by 8.22% to $53.5 million in 2025.
- According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $53.5 million, $49.7 million, and $49.4 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 53.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 53.50 Mn |
| Apr 30, 2025 | 49.65 Mn |
| Dec 31, 2024 | 49.43 Mn |
| Oct 31, 2024 | 46.46 Mn |
| Jul 31, 2024 | 46.23 Mn |
| Apr 30, 2024 | 36.79 Mn |
| Jan 31, 2024 | 34.72 Mn |
| Oct 31, 2023 | 34.57 Mn |
| Jul 31, 2023 | 34.41 Mn |
| Apr 30, 2023 | 27.89 Mn |
| Jan 31, 2023 | 28.28 Mn |
| Oct 31, 2022 | 24.58 Mn |
| Jul 31, 2022 | 24.56 Mn |
| Apr 30, 2022 | 24.47 Mn |
| Jan 31, 2022 | 24.45 Mn |
| Oct 31, 2021 | 24.44 Mn |
| Jul 31, 2021 | 24.43 Mn |
| Apr 30, 2021 | 19.09 Mn |
| Jan 31, 2021 | 17.96 Mn |
| Oct 31, 2020 | 17.88 Mn |
| Jul 31, 2020 | 17.85 Mn |
| Apr 30, 2020 | 17.75 Mn |
| Jan 31, 2020 | 17.84 Mn |
| Oct 31, 2019 | 17.66 Mn |
| Jul 31, 2019 | 17.49 Mn |
| Apr 30, 2019 | 15.08 Mn |
| Jan 31, 2019 | 14.38 Mn |
| Oct 31, 2018 | 15.11 Mn |
| Jul 31, 2018 | 10.80 Mn |
| Apr 30, 2018 | 10.32 Mn |
| Jan 31, 2018 | 10.79 Mn |
| Oct 31, 2017 | 9.86 Mn |
| Jul 31, 2017 | 9.71 Mn |
| Apr 30, 2017 | 4.65 Mn |
| Jan 31, 2017 | 7.66 Mn |
| Oct 31, 2016 | 709,500.00 |
| Jul 31, 2016 | 671,939.00 |
| Mar 31, 2016 | 26.33 Mn |
| Dec 31, 2015 | 19.08 Mn |
| Sep 30, 2015 | 26.32 Mn |
| Jun 30, 2015 | 11.72 Mn |
| Mar 31, 2015 | 124,729.00 |
| Dec 31, 2014 | 612,525.00 |
| Sep 30, 2014 | 678,189.00 |
| Jun 30, 2014 | 618,451.00 |
| Mar 31, 2014 | 459,286.00 |